Protagonist Therapeutics
PTGX
PTGX
129 hedge funds and large institutions have $398M invested in Protagonist Therapeutics in 2022 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 40 increasing their positions, 40 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
0% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 40
6% less capital invested
Capital invested by funds: $422M → $398M (-$24.2M)
13.45% less ownership
Funds ownership: 109.63% → 96.17% (-13%)
Holders
129
Holding in Top 10
1
Calls
$7.01M
Puts
$858K
Top Buyers
| 1 | +$6.68M | |
| 2 | +$4.38M | |
| 3 | +$3.8M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$2.96M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.14M |
Top Sellers
| 1 | -$17.7M | |
| 2 | -$12.8M | |
| 3 | -$8.76M | |
| 4 |
CAC
Cowen and Company
New York
|
-$8.43M |
| 5 |
Millennium Management
New York
|
-$7.51M |